Related Experiment Video

Updated: Jul 13, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Erlotinib in non-small cell lung cancer treatment: current status and future development

Cesare Gridelli1, Maria Anna Bareschino, Clorinda Schettino

  • 1Division of Medical Oncology, SG Moscati Hospital, Città Ospedaliera, Contrada Amoretta, Avellino, Italy. cgridelli@libero.it

The Oncologist
|August 4, 2007
PubMed

Insights

Erlotinib improves survival and quality of life for non-small cell lung cancer (NSCLC) patients. Ongoing research explores its use in various treatment settings and combinations for advanced NSCLC.

Area of Science:

  • Oncology
  • Molecular Targeted Therapy
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality globally.
  • Conventional treatments like chemotherapy and radiotherapy have limited efficacy in advanced NSCLC.
  • Novel molecular-targeted therapies are crucial for improving patient outcomes.

Purpose of the Study:

  • To review the role of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in NSCLC treatment.
  • To highlight erlotinib's efficacy in various treatment lines and its potential predictive factors.
  • To outline future research directions for erlotinib in NSCLC management.

Main Methods:

  • Review of clinical studies and data on erlotinib in advanced and metastatic NSCLC.
  • Analysis of erlotinib's efficacy in first-line, second-line, and third-line settings.
  • Investigation of clinical, pathologic, and molecular factors predicting erlotinib response.

Main Results:

  • Erlotinib demonstrates significant improvements in median survival, quality of life, and symptom management in advanced NSCLC.
  • Erlotinib shows notable antitumor activity as a first-line treatment option.
  • Predictive factors for erlotinib efficacy are under active investigation.

Conclusions:

  • Erlotinib is a valuable therapeutic option for advanced NSCLC, offering survival and quality-of-life benefits.
  • Further research is warranted to optimize erlotinib's use in adjuvant, neoadjuvant, and combination therapies.
  • Understanding predictive biomarkers will enhance personalized treatment strategies for NSCLC patients receiving erlotinib.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...